{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:32:10Z","timestamp":1777883530019,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021069","name":"Indivior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp;amp; Addiction Journal"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>North America is facing an unprecedented public health emergency of opioid-related morbidity and mortality. The mortality benefits of oral medication treatment for opioid use disorder (MOUD), such as methadone or buprenorphine, are well documented. However, barriers to access and long-term engagement have prevented maximizing their benefits. Long-acting injectable buprenorphine formulations were developed to address some of the challenges associated with oral MOUD. The \u201cPilot study to assess the feasibility, efficacy, and safety of extended-release injectable buprenorphine for the treatment of opioid use disorder among individuals at high risk of overdose\u201d (FASTER-BUP) was developed to explore this treatment option in populations at high risk of overdose in a real-world Canadian setting. FASTER-BUP is a 24-week observational prospective study evaluating the feasibility and clinical utility of extended-release injectable buprenorphine (XR-BUP) for the treatment of opioid use disorder (OUD) among 40 adults at high risk of overdose (ie, lifetime history of overdose or a positive urine drug test (UDT) for fentanyl within 30\u2009days prior to screening) in Vancouver, BC. The primary outcome is retention in treatment and secondary outcomes include: use of unregulated opioids, safety, overdose events, treatment satisfaction, changes in drug-related problems, changes in quality of life, opioid cravings, health service utilization, and criminal activity. FASTER-BUP is the first study to explore XR-BUP among individuals at high risk of overdose in a real-world Canadian setting. This commentary provides a brief narrative about the study thus far and presents insights on key adaptations to the study protocol, including those adopted to mitigate recruitment challenges.<\/jats:p>","DOI":"10.1177\/29767342231222103","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:08:36Z","timestamp":1705968516000},"page":"176-180","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["The FASTER-BUP Study, Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose: Protocol for an Observational Prospective Study"],"prefix":"10.1177","volume":"45","author":[{"given":"Jenna","family":"Langlois","sequence":"first","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"},{"name":"Faculty of Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonaid","family":"Nolan","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"},{"name":"Faculty of Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piper","family":"Dickhout","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zishan","family":"Cui","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"},{"name":"School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh","family":"Paterson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Fairbairn","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"},{"name":"Faculty of Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-7049","authenticated-orcid":false,"given":"M. Eugenia","family":"Soc\u00edas","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, BC, Canada"},{"name":"Faculty of Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"bibr1-29767342231222103","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses. Apparent opioid and stimulant toxicity deaths: surveillance of opioid- and stimulant-related harms in Canada. Ottawa; 2023."},{"key":"bibr2-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2009.00057.x"},{"key":"bibr3-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.02.024"},{"key":"bibr4-29767342231222103","doi-asserted-by":"publisher","DOI":"10.24095\/hpcdp.38.9.04"},{"key":"bibr5-29767342231222103","unstructured":"British Columbia Centre on Substance Use and BC Ministry of Health. A guideline for the clinical management of opioid use disorder. 2017. Accessed May 31, 2023. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2017\/06\/BC-OUD-Guidelines_June2017.pdf"},{"key":"bibr6-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-017-0783-9"},{"key":"bibr7-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1111\/add.14636"},{"key":"bibr8-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32259-1"},{"key":"bibr9-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.1052"},{"key":"bibr10-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.23032"},{"key":"bibr11-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1111\/add.15627"},{"key":"bibr12-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106014"},{"key":"bibr13-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-022-00286-6"},{"key":"bibr14-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-021-00223-z"},{"key":"bibr15-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108316"},{"key":"bibr16-29767342231222103","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06595-0"},{"key":"bibr17-29767342231222103","unstructured":"Canadian Research Initiative in Substance Misuse. National injectable opioid agonist treatment for opioid use disorder clinical guideline. 2019. Accessed May 31, 2023. https:\/\/crism.ca\/wp-content\/uploads\/2019\/09\/CRISM_National_IOAT_Clinical_Guideline-10Sep2019-English-FINAL.pdf"}],"container-title":["Substance Use &amp;amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342231222103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342231222103","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342231222103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:49:14Z","timestamp":1777600154000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342231222103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1177\/29767342231222103"],"URL":"https:\/\/doi.org\/10.1177\/29767342231222103","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}